---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-000067"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:34:46.503137+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Silexion CEO letter details 2025 progress; Phase 2/3 trial in LAPC set for H1 2026

## Summary
- SIL204 showed >90% inhibition in human cancer cell lines across 8 KRAS mutations and 5 tumor types.
- Positive regulatory feedback from Germany's BfArM on Phase 2/3 design; toxicology studies completed.
- Phase 2/3 LAPC trial initiation planned H1 2026; US IND expected H2 2026.
- Company raised over $18M in 2025 and regained Nasdaq compliance; addressable market >$30B.

## SEC filing metadata
- accession: 0001178913-26-000067
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326000067/0001178913-26-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326000067/zk2634187.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-000067
- JSON: https://secwatch.observer/filing/0001178913-26-000067.json
- Plain text: https://secwatch.observer/filing/0001178913-26-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.